$IRadimed (IRMD.US)$🎯 April 10, 2024, the current price is ...

New data: 23Q2, 23Q3, 23Q4, revenue, operating profit, and net income continue to grow.

In 2023, revenue increased by 23%, operating profit increased by 28.2%, net income increased by 34%, and return on equity increased to 23.7%.

The asset-liability ratio increased from 13.9% to 22.5%, total assets increased, but net assets decreased instead. On the asset side, cash flow went to inventory, fixed assets increased, on the liability side, accounts payable increased significantly, indicating benign liabilities.

Currently, the PE ratio is 31.33, which is not considered high compared to the growth rate, so it is still advisable to choose carefully (⭐️).